Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Wednesday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 0.9 %

Eagle Pharmaceuticals stock opened at $1.16 on Wednesday. The company has a 50 day moving average price of $0.87 and a 200-day moving average price of $1.60. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.74.

Institutional Trading of Eagle Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of EGRX. Creative Planning bought a new stake in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $59,000. Jane Street Group LLC bought a new position in Eagle Pharmaceuticals in the third quarter worth approximately $96,000. DGS Capital Management LLC raised its stake in Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 22,239 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Eagle Pharmaceuticals in the third quarter worth approximately $453,000. Finally, RBF Capital LLC raised its stake in Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares in the last quarter. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.